PT2153829E - Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas - Google Patents

Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas Download PDF

Info

Publication number
PT2153829E
PT2153829E PT90052952T PT09005295T PT2153829E PT 2153829 E PT2153829 E PT 2153829E PT 90052952 T PT90052952 T PT 90052952T PT 09005295 T PT09005295 T PT 09005295T PT 2153829 E PT2153829 E PT 2153829E
Authority
PT
Portugal
Prior art keywords
treating
preventing
methods
protein aggregation
diagnosing disorders
Prior art date
Application number
PT90052952T
Other languages
English (en)
Inventor
Joanne Mclaurin
Original Assignee
Joanne Mclaurin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joanne Mclaurin filed Critical Joanne Mclaurin
Publication of PT2153829E publication Critical patent/PT2153829E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
PT90052952T 2003-02-27 2004-02-27 Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas PT2153829E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45136303P 2003-02-27 2003-02-27
US52095803P 2003-11-17 2003-11-17
US52353403P 2003-11-19 2003-11-19
US10/787,621 US7521481B2 (en) 2003-02-27 2004-02-26 Methods of preventing, treating and diagnosing disorders of protein aggregation

Publications (1)

Publication Number Publication Date
PT2153829E true PT2153829E (pt) 2014-10-16

Family

ID=32931587

Family Applications (3)

Application Number Title Priority Date Filing Date
PT04715226T PT1608350E (pt) 2003-02-27 2004-02-27 Métodos de prevenção, tratamento e diagnóstico de distúrbios da agregação de proteínas
PT90052952T PT2153829E (pt) 2003-02-27 2004-02-27 Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas
PT100104777T PT2311445E (pt) 2003-02-27 2004-02-27 Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT04715226T PT1608350E (pt) 2003-02-27 2004-02-27 Métodos de prevenção, tratamento e diagnóstico de distúrbios da agregação de proteínas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT100104777T PT2311445E (pt) 2003-02-27 2004-02-27 Métodos para prevenir, tratar e diagnosticar distúrbios da agregação de proteínas

Country Status (15)

Country Link
US (7) US7521481B2 (pt)
EP (4) EP1608350B1 (pt)
JP (4) JP4999453B2 (pt)
AT (1) ATE432694T1 (pt)
AU (2) AU2004216544B2 (pt)
BR (1) BRPI0407910A (pt)
CA (1) CA2516563C (pt)
CY (2) CY1109338T1 (pt)
DE (1) DE602004021362D1 (pt)
DK (3) DK2311445T3 (pt)
ES (3) ES2327521T3 (pt)
IL (2) IL170476A (pt)
PT (3) PT1608350E (pt)
SI (3) SI2153829T1 (pt)
WO (1) WO2004075882A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046334A2 (en) * 2002-11-19 2004-06-03 Board Of Trustees Operating Michigan State University Antioxidant and antimicrobial agents and methods of use thereof
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PL1641914T3 (pl) 2003-06-27 2017-01-31 DePuy Synthes Products, Inc. Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
WO2005009291A2 (en) * 2003-07-23 2005-02-03 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
CA2626005A1 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
JP5249043B2 (ja) 2005-12-12 2013-07-31 エーシー イミューン ソシエテ アノニム 治療ワクチン
EP1993523A4 (en) * 2006-02-17 2009-06-10 Joanne Mclaurin COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
US8676323B2 (en) * 2006-03-09 2014-03-18 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
BRPI0708725A2 (pt) * 2006-03-09 2011-06-07 Waratah Pharmaceuticals Inc formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna
AU2007265631B2 (en) * 2006-06-23 2012-11-08 The Feinstein Institute For Medical Research Inhibitors of A-Beta and synuclein aggregation
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20100292157A1 (en) * 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2008124929A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES
JP2010523602A (ja) * 2007-04-12 2010-07-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
WO2008124930A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
WO2008144578A1 (en) * 2007-05-17 2008-11-27 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8478412B2 (en) * 2007-10-30 2013-07-02 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US20090131857A1 (en) * 2007-11-20 2009-05-21 Mark Geiger Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
CA2978149C (en) * 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
WO2010040232A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
CA2756600C (en) 2009-03-26 2019-08-20 Advanced Technologies And Regenerative Medicine, Llc Human umbilical cord tissue cells as therapy for alzheimer's disease
US20100249073A1 (en) * 2009-03-27 2010-09-30 Robert Sabin Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein
EP2545023A4 (en) * 2010-02-15 2017-04-12 Abbvie Inc. Process for the preparation of scyllo-inositol
CN103402954A (zh) 2010-10-13 2013-11-20 依兰制药公司 鲨肌醇和相关化合物的合成方法
JP5980790B2 (ja) 2010-11-05 2016-08-31 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
CA2837926A1 (en) * 2011-06-03 2012-12-20 Susan ABUSHAKRA Scyllo - inositol for the treatment of behavioral and psychiatric disorders
KR101365711B1 (ko) * 2013-04-30 2014-02-21 재단법인 경북해양바이오산업연구원 효모로부터 분리된 신규한 생물학적 계면활성제
EP3161018A4 (en) 2014-06-25 2018-01-24 Rensselaer Polytechnic Institute Oxetane polymers and methods of preparation thereof
WO2016047823A1 (ko) * 2014-09-25 2016-03-31 영남대학교 산학협력단 장구채 추출물 또는 이로부터 분리된 보르네시톨을 유효성분으로 함유하는 세포 노화 억제용 조성물
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US20170354669A1 (en) * 2016-02-24 2017-12-14 The Trustees Of Columbia University In The City Of New York Disruption of the interaction between amyloid beta peptide and dietary lipids
AU2017318672B2 (en) 2016-09-01 2022-03-10 Nutrition 21, Llc Magnesium biotinate compositions and methods of use
WO2018191415A1 (en) 2017-04-11 2018-10-18 Colorado State University Research Foundation Functionalization of metal-organic frameworks
EP3793619A4 (en) 2018-05-16 2022-01-12 Emory University STYRYLBENZOTHIAZOLE DERIVATIVES AND THEIR USES IN IMAGING
MX2021005213A (es) * 2018-11-02 2021-09-08 Nutrition 21 Llc Composiciones que contienen complejos de silicato de arginina estabilizado con inositol y inositol para mejorar funciones cognitivas en jugadores de videojuegos.
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
EP3789018A1 (en) * 2019-09-09 2021-03-10 Servicio Andaluz De Salud Composition and methods for enhancing or promoting the secretion of ghrelin to promote a healthy metabolic aging
CA3165102A1 (en) 2019-12-16 2021-06-24 Nutrition 21, Llc Methods of production of arginine-silicate complexes
JP2023510525A (ja) * 2020-01-03 2023-03-14 バイオサーチ，エス．エー． 認知障害の治療に使用する組成物
WO2022059776A1 (ja) * 2020-09-17 2022-03-24 昭和電工株式会社 オートファジー活性化剤
WO2024054415A1 (en) * 2022-09-07 2024-03-14 Eirgen Pharma, Ltd. A combination of scyllo-inositol and flavones

Family Cites Families (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2088897A (en) * 1935-03-25 1937-08-03 Goss Printing Press Co Ltd Printing press
US2557381A (en) * 1946-08-09 1951-06-19 William C Huebner Multiple unit printing press
DE2234089C3 (de) * 1972-07-08 1975-01-23 Automatic Druckmaschinenfabrik Dr. W. Hinniger U. Soehne, 1000 Berlin Offset-Rollen-Rotationsdruckmaschine
GB1581233A (en) * 1976-06-02 1980-12-10 Drg Uk Ltd Printing press
US4201706A (en) * 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
DE3405663A1 (de) 1984-02-17 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung von scyllo-inosit
US5545632A (en) 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5023248A (en) * 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US5407924A (en) 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3610107A1 (de) * 1986-03-26 1987-10-08 Voith Gmbh J M Stellvorrichtung zum verstellen einer walze
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US4758420A (en) * 1986-07-14 1988-07-19 The Dow Chemical Company Solvent extraction of polychlorinated organic compounds from porous materials
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
JPH067158Y2 (ja) 1987-03-18 1994-02-23 株式会社藤井合金製作所 配管端末の防水構造
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3808142A1 (de) * 1988-03-11 1989-09-21 Goebel Gmbh Maschf Lagereinrichtung
DE3814752C1 (pt) * 1988-04-30 1989-08-31 J.M. Voith Gmbh, 7920 Heidenheim, De
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
JPH03102492A (ja) 1989-06-12 1991-04-26 Mitsui Eng & Shipbuild Co Ltd 自動販売機のデータ送信システムおよび複合機能型自動販売機
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5111814A (en) * 1990-07-06 1992-05-12 Thomas Jefferson University Laryngeal pacemaker
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
JP2984043B2 (ja) 1990-09-18 1999-11-29 旭化成工業株式会社 ミオ・イノシトールデヒドロゲナーゼおよびその製造法
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
JPH05192163A (ja) 1991-09-30 1993-08-03 Suntory Ltd イノシトールデヒドロゲナーゼ遺伝子
CA2125964C (en) 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JP3251976B2 (ja) 1992-06-23 2002-01-28 旭化成株式会社 ミオ・イノシトールデヒドロゲナーゼを生産する実質上純粋な微生物
US5351616A (en) * 1992-08-13 1994-10-04 Man Roland Druckmaschinen Ag Rotary web printing machine, particularly for printing on thick or carton-type stock webs with replaceable plate cylinders
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
NZ314111A (en) * 1992-10-05 1997-08-22 Virginia Tech Intell Prop Preparation of d-chiro-inositol by reducing d-chiro-3-inosose
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
ATE244302T1 (de) * 1993-04-05 2003-07-15 Aveve Nv Phytate-hydrolyse und enzymatische zusammensetzung für die hydrolyse von phytat
DK0712827T3 (da) * 1993-08-11 1999-09-20 Zaidan Hojin Biseibutsu Fremgangsmåde til fremstilling af D-chiro-inositol
US5412080A (en) 1993-08-25 1995-05-02 President And Fellow Of Harvard College Enterobactin compounds
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
DE4408025A1 (de) * 1994-03-10 1995-09-14 Koenig & Bauer Ag Druckwerk für eine Mehrfarbenrollenrotationsdruckmaschine
DE4430693B4 (de) * 1994-08-30 2005-12-22 Man Roland Druckmaschinen Ag Antriebe für eine Rollenrotations-Offsetdruckmaschine
US5550166A (en) 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP3630344B2 (ja) 1995-11-17 2005-03-16 北興化学工業株式会社 イノシトール立体異性体の製造方法
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
AU1153097A (en) * 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
EP1642575B1 (en) 1997-03-10 2009-10-28 Loma Linda University Medical Center Use of r-carprofen for the prevention of alzheimer's disease
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
GB9801899D0 (en) 1998-01-29 1998-03-25 Univ London Neurotrophic properties of ipgs analogues
DE19805898C2 (de) * 1998-02-13 2003-09-18 Roland Man Druckmasch Druckwerk für eine Rollenrotationsdruckmaschine
US6720190B1 (en) * 1998-03-27 2004-04-13 Ole Hindsgaul Methods for screening compound libraries
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6227110B1 (en) * 1998-06-23 2001-05-08 Heidelberger Druckmaschinen Ag Wet printing press with throw-off mechanism
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
KR20070004143A (ko) 1998-09-24 2007-01-05 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
AUPP675898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
GB2389182B (en) 1999-02-10 2004-02-04 Elan Pharm Inc Method of purifying b-secretase
JP4653318B2 (ja) * 1999-02-10 2011-03-16 エラン ファーマシューティカルズ，インコーポレイテッド βセクレターゼ酵素組成物および方法
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US6818430B1 (en) 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6864240B1 (en) * 1999-06-15 2005-03-08 Elan Pharmaceuticals, Inc. Dipeptide inhibitors of β-secretase
AU5619400A (en) 1999-06-15 2001-01-02 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
AU5994900A (en) 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
DE19937803A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
DE19937805A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
DE19937796B4 (de) * 1999-08-10 2007-03-22 Man Roland Druckmaschinen Ag Druckwerk
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
JP2001163810A (ja) 1999-09-30 2001-06-19 Microbial Chem Res Found １ｄ−キロ−イノシトールの新規合成方法および中間体
JP2003511094A (ja) * 1999-10-18 2003-03-25 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪体重及び体力を増強するための食物補充物質
US7728043B2 (en) * 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
EP1235789A2 (en) 1999-11-09 2002-09-04 Eli Lilly And Company $g(b)-AMINOACID COMPOUNDS USEFUL FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
JP2003513958A (ja) 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
DE19963944C1 (de) * 1999-12-31 2001-06-13 Koenig & Bauer Ag Verfahren zum Einstellen einer Walze einer Druckmaschine
EP1254108A1 (en) * 2000-01-24 2002-11-06 MERCK SHARP & DOHME LTD. Gamma-secretase inhibitors
DE10008215B4 (de) * 2000-02-23 2013-03-28 Manroland Web Systems Gmbh Druckwerk für eine Rotationsdruckmaschine mit Kreuzschlitten
GB0005251D0 (en) * 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
US7365196B2 (en) 2000-03-20 2008-04-29 Merck Sharp & Dohme Ltd. Sulphonamido-substituted bridged bicycloalkyl derivatives
US7119085B2 (en) * 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
AU2001257022B2 (en) 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US6716826B2 (en) * 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US6939857B2 (en) * 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
GB0015627D0 (en) 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
US7034182B2 (en) 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
DE10031955A1 (de) 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
GB0016681D0 (en) * 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6559891B1 (en) * 2000-08-15 2003-05-06 Sony Corporation Method and apparatus to generate tri-level HDTV synchronization pulses
CA2465534C (en) 2000-11-02 2009-10-27 Nigel H. Greig Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
US7138400B2 (en) 2000-11-02 2006-11-21 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
JP3887600B2 (ja) 2001-01-15 2007-02-28 北興化学工業株式会社 Ｄ−ミオ−イノシトール１−エピメラーゼをコードするｄｎａ
US8034803B2 (en) * 2001-02-06 2011-10-11 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
EP1233021A3 (en) * 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
ES2281603T3 (es) * 2001-04-09 2007-10-01 KOENIG & BAUER AKTIENGESELLSCHAFT Mecanismo de impresion de una maquina impresora.
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
EP1395275B1 (en) 2001-05-22 2008-11-12 Merck & Co., Inc. Beta-secretase substrate and uses thereof
CA2448084A1 (en) 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
AU2002314914A1 (en) 2001-06-01 2002-12-16 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
US6684775B2 (en) * 2001-06-07 2004-02-03 Heidelberger Druckmaschinen Ag Printing unit with roll-away inkers
MXPA03011399A (es) 2001-06-08 2004-07-01 Elan Pharm Inc Metodos para tratar la enfermedad de alzheimer.
WO2002100820A1 (en) 2001-06-11 2002-12-19 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of alzheimer's disease
CA2450202A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
CA2450167A1 (en) 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
MXPA03011521A (es) * 2001-06-13 2004-03-18 Elan Pharm Inc Aminadioles para tratamiento de enfermedad de alzheimer.
ATE323489T1 (de) 2001-06-25 2006-05-15 Elan Pharm Inc Verwendung von bicyklischen verbindungen für die behandlung von alzheimer
JP3981597B2 (ja) 2001-06-25 2007-09-26 北興化学工業株式会社 シロ−イノソースの製造法及びシロ−イノシトールの製造法
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
EP1404328A1 (en) 2001-07-10 2004-04-07 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease
MXPA04000337A (es) 2001-07-10 2004-07-23 Upjohn Co Amindioles para tratamiento de enfermedad de alzheimer.
MXPA04000338A (es) 2001-07-10 2004-07-23 Upjohn Co Diamindioles para tratamiento de enfermedad de alzheimer.
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US7122675B2 (en) * 2001-08-03 2006-10-17 Schering Corporation Gamma secretase inhibitors
WO2003014075A2 (en) * 2001-08-03 2003-02-20 Schering Corporation Novel gamma secretase inhibitors
CA2483959A1 (en) 2001-08-28 2003-03-13 Elan Pharmaceuticals, Inc. Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons
DE10145322A1 (de) * 2001-09-14 2003-04-03 Ina Schaeffler Kg Lageranordnung für Zylinder, Walzen oder Trommeln
MXPA04002785A (es) 2001-09-24 2004-07-29 Elan Pharm Inc Aminas sustituidas para tratamiento de enfermedad de alzheimer.
BR0213139A (pt) 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
WO2003030886A2 (en) 2001-10-05 2003-04-17 Elan Pharmaceuticals, Inc Allylamides useful in the treatment of alzheimer's disease
CA2464736A1 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
BR0213743A (pt) 2001-10-29 2004-12-21 Upjohn Co Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
IL161881A0 (en) 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
AP2004003052A0 (en) 2001-11-19 2004-06-30 Elan Pharm Inc 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines.
EP1458378B1 (en) 2001-11-21 2006-05-24 Elan Pharmaceuticals, Inc. Amino acid derivatives useful for the treatment of alzheimer's disease
EP1450795A1 (en) 2001-12-04 2004-09-01 Elan Pharmaceuticals, Inc. Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
BR0214736A (pt) 2001-12-06 2004-11-23 Elan Pharm Inc Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições
CH698246B1 (de) 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US7910586B2 (en) * 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
JP2005534614A (ja) 2002-01-04 2005-11-17 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミノカルボキサミド
WO2003059346A1 (en) 2002-01-18 2003-07-24 The Genetics Company Inc. Beta-secretase inhibitors
WO2003064396A1 (en) 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) * 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
CN1319987C (zh) 2002-04-24 2007-06-06 森启 γ－分泌酶抑制剂
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE60328182D1 (de) * 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
WO2003094854A2 (en) 2002-05-07 2003-11-20 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
DE10223666B4 (de) * 2002-05-28 2006-06-14 Windmöller & Hölscher Kg Farbwerksaufbau bei Flexodruckmaschinen
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20060154926A1 (en) 2002-06-11 2006-07-13 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
WO2003103652A1 (en) 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
WO2004002478A1 (en) 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
BR0314071A (pt) 2002-09-06 2005-07-05 Pharmacia & Upjohn Co Llc Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1542964A2 (en) 2002-09-27 2005-06-22 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer's disease
WO2004031669A1 (en) 2002-09-30 2004-04-15 Bp Corporation North America Inc. Reduced carbon dioxide emission system and method for providing power for refrigerant compression and electrical power for a light hydrocarbon gas liquefaction process
CA2501091A1 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
DE60230455D1 (de) * 2002-10-17 2009-01-29 Jingyu Liang Natürliche verbindung für die behandlung von diabetes, deren herstellung und verwendung
US7351738B2 (en) 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
PL377777A1 (pl) 2002-12-11 2006-02-20 Pharmacia & Upjohn Company Llc Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków
FR2848452B1 (fr) 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
WO2004069826A1 (en) 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
CL2004000848A1 (es) 2003-04-21 2005-01-28 Elan Pharmaceuticals Inc Pharm Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
MXPA05011150A (es) 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
TW200510405A (en) * 2003-05-13 2005-03-16 Schering Corp Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
JP4818114B2 (ja) 2003-05-16 2011-11-16 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害剤としてのシクロヘキシルスルホン類
US7060698B2 (en) 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
WO2005009344A2 (en) 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7291620B2 (en) 2003-06-30 2007-11-06 Merck + Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
EP1643986A4 (en) 2003-07-01 2009-04-08 Merck & Co Inc PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2005008250A1 (en) 2003-07-21 2005-01-27 Angiogenetics Sweden Ab Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1660443B1 (en) * 2003-08-08 2009-03-04 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
CN1835936A (zh) 2003-08-14 2006-09-20 默克公司 用于治疗阿尔茨海默氏病的大环β－分泌酶抑制剂
ATE509917T1 (de) 2003-09-24 2011-06-15 Merck Sharp & Dohme Gamma-secretase-inhibitoren
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
GB0323258D0 (en) * 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
HUE025548T2 (en) 2003-10-06 2016-02-29 Hoffmann La Roche Substituted dibenzo-azepine and benzodiazepine derivatives useful as gamma-secretase inhibitors
CA2774930C (en) 2003-10-14 2014-08-05 Hokko Chemical Industry Co., Ltd. Method for producing purified scyllo-inositol utilizing boric acid
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0326039D0 (en) * 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
EP1685142B1 (en) 2003-11-11 2008-01-09 F. Hoffmann-La Roche Ag Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A1 (en) 2003-11-24 2005-06-09 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005058857A1 (en) 2003-11-28 2005-06-30 F. Hoffmann-La Roche Ag Tetronic and tetramic acids as inhibitors of beta-secrease
JP2007517781A (ja) 2003-12-19 2007-07-05 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
KR100803996B1 (ko) 2003-12-31 2008-02-18 포항공과대학교 산학협력단 아밀로이드 전구체 단백질 프로세싱 저해제
ES2300852T3 (es) 2004-01-29 2008-06-16 Cellzome Ag Tratamiento de enfermedades neurogenerativas mediante el uso de gpr49.
AU2004315399B2 (en) 2004-01-29 2009-08-06 Cellzome Ag Treatment of neurodegenerative diseases by the use of ATP7A-modulators
BRPI0509186A (pt) 2004-03-25 2007-08-28 Elan Pharm Inc 1,3-diaminopropanos 2-amino-e 2-tio-substituìdos
US20070203147A1 (en) 2004-03-30 2007-08-30 Coburn Craig A 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
JP2007531742A (ja) 2004-04-05 2007-11-08 シェーリング　コーポレイション 新規のγセクレターゼインヒビター
JP4764418B2 (ja) 2004-04-20 2011-09-07 メルク・シャープ・エンド・ドーム・コーポレイション アルツハイマー病の治療のためのβ−セクレターゼ阻害剤として有用な２，４，６−置換ピリジル誘導体化合物
CN1942457A (zh) 2004-04-20 2007-04-04 默克公司 作为β－促分泌酶抑制剂用于阿尔茨海默氏病的治疗中的1,3,5－取代的苯基衍生化合物
EP1756040A4 (en) * 2004-05-13 2008-04-30 Merck & Co Inc PHENYL CARBOXAMIDE COMPOUNDS FOR USE AS BETA SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
US20060004096A1 (en) * 2004-05-28 2006-01-05 Joseph Larner Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
JP4406327B2 (ja) 2004-06-29 2010-01-27 儀昭 新田 タイヤチップ製造装置
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CN103301094A (zh) 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006112000A1 (ja) 2005-03-30 2006-10-26 The Niigata Institute Of Science And Technology 大腸菌変異株による２－デオキシ－シロ－イノソースの合成および精製する方法並びに得られた２－デオキシ－シロ－イノソース
KR20060105233A (ko) 2005-04-02 2006-10-11 삼성전자주식회사 하이브리드 디스크, 그 기록 및/또는 재생 장치 및 방법
US7273882B2 (en) 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007019080A2 (en) 2005-08-03 2007-02-15 Merck & Co., Inc. Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007021793A1 (en) 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
CA2626005A1 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
ATE502036T1 (de) * 2005-10-25 2011-04-15 Janssen Pharmaceutica Nv Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4- düpyrimidinderivate
US20070197452A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
CA2579188A1 (en) 2006-02-17 2007-08-17 Joanne Mclaurin Treatment of amyloid-related diseases
EP1993523A4 (en) 2006-02-17 2009-06-10 Joanne Mclaurin COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
BRPI0708725A2 (pt) 2006-03-09 2011-06-07 Waratah Pharmaceuticals Inc formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna
WO2007134434A1 (en) 2006-05-18 2007-11-29 Merck Frosst Canada Ltd. Phenanthrene derivatives as mpges-1 inhibitors
CA2652449A1 (en) 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
EP1884531A1 (en) 2006-07-30 2008-02-06 Lonza Compounds GmbH & Co. KG Sheet molding compounds (smc) comprising thermosetting resins based on renewable resources
US20080064725A1 (en) 2006-08-25 2008-03-13 Allan Basbaum Intrathecal administration of triptan compositions to treat non-migraine pain
CN101511304A (zh) 2006-09-06 2009-08-19 奥尔特克斯公司 人工心脏瓣膜、系统和移植方法
US20100173960A1 (en) 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20100292157A1 (en) 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
WO2008082658A2 (en) 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications
WO2008098371A1 (en) 2007-02-16 2008-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Compositions and method for reducing amyloid beta in a mammal
WO2008124930A1 (en) 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
WO2008124929A1 (en) 2007-04-12 2008-10-23 Joanne Mclaurin USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES
JP2010523602A (ja) 2007-04-12 2010-07-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用
US20100144891A1 (en) 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
JP5034916B2 (ja) 2007-12-10 2012-09-26 富士通セミコンダクター株式会社 性能評価モデル生成方法、システム性能評価方法、及び性能評価モデル生成装置
EP2323704B1 (en) 2008-08-06 2018-02-28 Invista Technologies S.à.r.l. Preparation of elastic composite structures useful for components of disposable hygiene products and articles of apparel
JP5685192B2 (ja) * 2008-09-15 2015-03-18 エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 高尿酸血症と関連病態の治療の方法
WO2010040232A1 (en) 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
CA2837926A1 (en) 2011-06-03 2012-12-20 Susan ABUSHAKRA Scyllo - inositol for the treatment of behavioral and psychiatric disorders

Also Published As

Publication number Publication date
AU2009251035A1 (en) 2010-01-14
BRPI0407910A (pt) 2006-02-14
US20140073701A1 (en) 2014-03-13
EP2153829B1 (en) 2014-08-13
CA2516563C (en) 2013-08-20
US9833420B2 (en) 2017-12-05
EP1608350B1 (en) 2009-06-03
CY1115732T1 (el) 2017-01-25
ATE432694T1 (de) 2009-06-15
IL170476A (en) 2013-05-30
CA2516563A1 (en) 2004-09-10
JP2016117743A (ja) 2016-06-30
US20150164821A1 (en) 2015-06-18
JP2006522740A (ja) 2006-10-05
JP2014065731A (ja) 2014-04-17
AU2004216544B2 (en) 2009-09-24
AU2009251035B2 (en) 2012-12-13
SI2311445T1 (sl) 2014-08-29
JP4999453B2 (ja) 2012-08-15
PT2311445E (pt) 2014-06-25
DK1608350T3 (da) 2009-09-07
IL220065A0 (en) 2012-09-24
EP2311445A1 (en) 2011-04-20
US20150031776A1 (en) 2015-01-29
WO2004075882A1 (en) 2004-09-10
ES2327521T3 (es) 2009-10-30
ES2475977T3 (es) 2014-07-11
AU2004216544A1 (en) 2004-09-10
US20120157549A1 (en) 2012-06-21
DE602004021362D1 (de) 2009-07-16
SI1608350T1 (sl) 2009-12-31
DK2311445T3 (da) 2014-06-16
EP2153829A1 (en) 2010-02-17
US20090227686A1 (en) 2009-09-10
CY1109338T1 (el) 2014-07-02
DK2153829T3 (da) 2014-10-27
US7521481B2 (en) 2009-04-21
EP1608350A1 (en) 2005-12-28
SI2153829T1 (sl) 2014-12-31
US20070078099A1 (en) 2007-04-05
US8859628B2 (en) 2014-10-14
EP2823813A1 (en) 2015-01-14
EP2311445B1 (en) 2014-03-26
JP2011105733A (ja) 2011-06-02
ES2520047T3 (es) 2014-11-11
IL220065A (en) 2015-08-31
US20040204387A1 (en) 2004-10-14
PT1608350E (pt) 2009-08-28

Similar Documents

Publication Publication Date Title
IL220065A0 (en) Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
EP2332569A3 (en) Compositions and methods for treating neurological disorders
WO2005066337A3 (en) Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
HK1080722A1 (en) The use of lactoferrin in the treatment of malignant neoplasms
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
IL197890A (en) Arylvinylchloroalkylan compounds and their preparation methods and uses
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
ZA201106419B (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
DE602005002776D1 (de) Verfahren zur Herstellung von 1,3-Dihydro-2H-3-Benzazepin-2-on und Anwendung zur Herstellung von Ivabradine und ihren pharmazeutischen annehmbaren Salzen
WO2007129221A8 (en) Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
WO2005060945A3 (en) Intranasal compositions comprising zolpidem
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
JP2003526659A5 (pt)
WO2002102412A3 (en) Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
CY1115261T1 (el) Μεθοδοι προληψης, θεραπειας και διαγνωσης διαταραχων της συσσωματωσης πρωτεϊνων
RU2003116249A (ru) Способ лечения псориаза